Journal of Clinical Oncology, Vol 1, 635-639, Copyright © 1983 by American Society of Clinical Oncology
Adrenocorticotropic hormone in the prevention of cisplatin-induced nausea and vomiting
N Colbert, V Izrael, JP Lotz, D Stoppa-Lyonnet, JM Vannetzel, F Pene, M Schlienger and A Laugier
A double-blind trial to evaluate the antiemetic effects of
adrenocorticotropic hormone (ACTH) in patients treated with cisplatin was
performed. Thirty-seven adults with advanced cancer who were treated with
cisplatin were randomly assigned to receive either synthetic long-acting
ACTH (1 mg IM given 24 hours, 12 hours, and immediately preceding the
administration of cisplatin) or a placebo given under the same conditions.
All of the patients received chlorpromazine (50 mg IM) 30 minutes before
cisplatin infusion. Patients receiving ACTH and chlorpromazine had
significantly fewer episodes of vomiting (p less than 0.01) and shorter
periods of nausea (p less than 0.02) than patients receiving placebo and
chlorpromazine. Patients receiving ACTH and chlorpromazine were
significantly more comfortable than patients receiving placebo and
chlorpromazine. No important side effects were observed. ACTH may be an
effective agent in preventing nausea and vomiting induced by cisplatin.